Full-Time

Sr. Oncology Sales Specialist-S2

Dallas, TX, Field based

Posted on 7/4/2026

Eisai

Eisai

Compensation Overview

$144.6k - $189.7k/yr

+ Incentive Plan

Dallas, TX, USA + 2 more

More locations: Longview, TX, USA | Tyler, TX, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Bachelor's degree with minimum 2+ years of relevant experience in specialty sales experience in device sales or related therapeutic area (Oncology sales experience preferred)
  • Minimum 3+ years of relevant experience in specialty sales experience in device sales or related therapeutic area (Oncology sales experience highly preferred)
Responsibilities
  • Responsible for meeting/exceeding Oncology sales goals for an assigned territory by promoting Oncology therapeutic products in a compliant and appropriate manner.
  • Collaborate with leaders and relevant cross-functional teams to develop and implement territory business strategies and drive pull-through sales within Integrated Delivery Networks.
  • Conduct ongoing territory and market analysis to monitor customer needs and preferences, and local market dynamics and trends.
  • Identify, build relationships with, and influence prescribers and decision-makers through understanding of issues and opportunities in territory.
  • Deliver clinical, efficacy, and safety messaging and information about product access / safe administration to relevant customer stakeholders in a compliant way.
  • Monitor operating costs and compliance with territory budget.
  • Seek out mentorship to learn and build key sales skills.
Desired Qualifications
  • Experience in hospital and large account sales, and documented history of successful sales performance in a competitive environment preferred.
  • Experience working with relevant customer business, disease state, product prescribing information, approved promotional clinical trials, patient access to medication, and regulatory/compliance guidelines preferred.
  • Experience with account planning and management preferred.
  • Experience working with key laws and regulations impacting the pharmaceutical industry (e.g., PhRMA Code; Federal Food, Drug, Cosmetic Act; Anti-Kickback Statute; False Claims Act, OIG/DOJ Guidance; Foreign Corrupt Practices Act; and federal and state transparency and disclosure laws) preferred.
  • Demonstrated skills at building and maintaining professional relationships with key customers and others in the customer influence network, preferred.
  • Experience in business analytics to understand and analyze business and market drivers, preferred.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • UK Hatfield in-house cold-chain capacity strengthens lecanemab supply resilience across Europe, Middle East, and Africa.
  • Taletrectinib MAA submission targets 80,000 ROS1-positive NSCLC patients in Europe, diversifying oncology pipeline revenue streams.
  • 48-month Clarity AD data at AD/PD 2026 reinforces lecanemab efficacy, supporting global market expansion in 53 approved countries.

What critics are saying

  • Lecanemab ARIA-H neurotoxicity in >10% APOE4 homozygotes may trigger FDA emergency withdrawal, collapsing $1.2B+ neurology revenue.
  • Taletrectinib EMA rejection due to TRUST-I/II data gaps blocks access to 80,000 ROS1 patients, jeopardizing oncology diversification.
  • Tazverik global discontinuation over 5.7% secondary hematologic malignancy risk erodes EZH2 inhibitor trust and $150M+ Japan revenue.

What makes Eisai unique

  • Eisai uniquely integrates cold-chain packaging for lecanemab via its £48M UK Hatfield hub, cutting external contract reliance.
  • Eisai’s Kompass platform co-developed with KidneyCAN delivers first-of-its-kind digital navigation for kidney cancer patients and caregivers.
  • Eisai holds native ROS1 inhibitor taletrectinib rights post-January 2026 acquisition, expanding oncology beyond lenvatinib partnerships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Remote Work Options

Home Office Stipend

Phone/Internet Stipend

Company News

Packaging World Insights
Jun 22nd, 2026
Eisai advances cold-chain pharma packaging capacity in UK.

Eisai advances cold-chain pharma packaging capacity in UK. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call

PR Newswire
Mar 26th, 2026
Eisai and Nuvation Bio submit MAA for taletrectinib in ROS1-positive NSCLC to EMA

Eisai and Nuvation Bio announced that the European Medicines Agency has validated their Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer. The filing will follow a standard review timeline and has been accepted for full approval consideration. Taletrectinib is already approved in the US, China and Japan for this indication. Additional filings are planned for the UK, Canada and other regions within Eisai's licensed territories following the January 2026 licensing and collaboration agreement between the companies. The application is based on data from two pivotal Phase 2 studies, TRUST-I and TRUST-II. Approximately 2% of NSCLC patients have ROS1-positive disease. Nearly 400,000 people are diagnosed with lung cancer in Europe annually, with NSCLC accounting for 80% of cases.

Japan Industry News
Mar 19th, 2026
Eisai to discontinue Tazverik sales in Japan amid safety concerns.

Eisai to discontinue Tazverik sales in Japan amid safety concerns. Eisai Co., Ltd. has announced plans to discontinue the administration and sales of its anticancer agent Tazverik (tazemetostat hydrobromide) in Japan. This decision follows the voluntary withdrawal of the product in the United States and other countries due to safety concerns. The company has been reviewing safety data from clinical trials and postmarketing reports, which revealed multiple cases of secondary hematologic malignancies associated with both combination and monotherapy treatments using tazemetostat. After a comprehensive evaluation, Eisai concluded that the risk of these malignancies necessitates discontinuing the drug in Japan, even under approved conditions of use. Eisai is currently communicating with medical institutions in Japan to ensure the immediate discontinuation of Tazverik for patients currently receiving it and to prevent the initiation of new treatments. The company emphasized its commitment to providing timely and appropriate information to healthcare professionals to minimize confusion or disruption. The SYMPHONY-1 trial, a phase 1b/3 study, is evaluating the efficacy of adding tazemetostat to the standard second-line treatment of rituximab plus lenalidomide (R2 therapy) in patients with relapsed or refractory follicular lymphoma. This trial is being conducted under Ipsen's leadership as a confirmatory trial for the accelerated approval of Tazverik in the United States and China, involving 229 sites across 15 countries. However, no sites in Japan are participating. Tazemetostat, a first-in-class oral small molecule inhibitor targeting EZH2, was developed under a collaboration between Eisai and Epizyme, Inc., an Ipsen company. Eisai holds exclusive development and commercialization rights for the agent in Japan.

Japan Industry News
Mar 17th, 2026
Eisai opens global IT hub in India to boost operations.

Eisai opens global IT hub in India to boost operations. Eisai Co., Ltd. has inaugurated the Eisai Global Capability Centre (EGCC) in Visakhapatnam, India, marking a significant step in the company's long-term IT strategy. The new center, located within the Eisai Knowledge Centre, aims to serve as the company's information technology hub. The opening ceremony featured notable attendees, including Muneo Takahashi, Consul General of Japan in Chennai, Keisuke Naito, Eisai's COO and Chief Growth Officer, Yumiko Aoyagi, First Secretary at the Embassy of Japan in India, and Vijaya Krishnan, IAS District Director of Anakapalli. The establishment of the EGCC is a core initiative of Eisai Group's strategy to integrate external expertise and cutting-edge technologies. The center will insource the design and operation of internal IT services, providing standardized, high-quality services in a secure environment to support Eisai's global operations. Initially, the EGCC will focus on standardizing global IT infrastructure operations. Its scope will gradually expand to include cybersecurity, data and analytics, and operational applications, adapting to business needs. Since 2009, the Eisai Knowledge Centre in Andhra Pradesh has been a core operational hub for global production and process research. The region is currently focused on establishing a "New IT City," aiming to create 300,000 IT jobs by attracting data centers and AI hubs. By establishing the EGCC in this location, Eisai plans to recruit and nurture global IT talent aligned with its "human health care" concept. The company aims to contribute to the local IT ecosystem and economic prosperity through long-term employment and career development opportunities.

Clival Private Limited
Mar 11th, 2026
Eisai to Present New Lecanemab Data at AD/PD 2026 Conference

Eisai to present new lecanemab data at AD/PD 2026 conference. Eisai Co., Ltd. will present new research on Lecanemab, its therapy for Alzheimer's disease, at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders 2026. The conference will take place March 17-21, 2026, in Copenhagen and online. Eisai plans to present six research updates, including three oral presentations and several poster sessions, highlighting real-world data and long-term outcomes associated with lecanemab. Focus on real-world outcomes and long-term data. The upcoming presentations will emphasize real-world clinical evidence and long-term treatment outcomes for patients receiving lecanemab. Key oral presentations will cover: * Safety and effectiveness of lecanemab in APOE4 homozygous patients based on data from the LEADER real-world study * Long-term treatment persistence and patient characteristics among individuals using lecanemab in routine clinical practice in the United States * A genome-wide association study identifying genetic variants linked to cognitive decline in Alzheimer's disease These findings aim to deepen understanding of how anti-amyloid therapies perform outside controlled clinical trials. Additional poster presentations. Four additional studies will be presented as posters at the conference. Highlights include: * 48-month results from the Clarity AD open-label extension study, focusing on patients who are APOE ε4 non-carriers and heterozygotes * Research examining how lecanemab reduces amyloid-beta protofibrils and how these reductions correlate with biomarkers linked to neuronal and synaptic health * Development of a fully automated plasma pTau205 immunoassay, created in collaboration with Sysmex Corporation Poster sessions will be available for viewing March 17-19 (CET). Industry symposium on early Alzheimer's intervention. Eisai will also host a sponsored symposium titled: "Continue Life Their Way: Early Intervention in Alzheimer's Disease." The session will feature global experts discussing several key topics: * Why early intervention is critical in Alzheimer's disease * Long-term evidence supporting continued treatment in early disease stages * How real-world data can guide clinical decision-making The symposium aims to highlight the importance of recognizing Alzheimer's disease as a chronic condition requiring multidisciplinary care. About lecanemab (LEQEMBI). Lecanemab is a humanized monoclonal antibody designed to target amyloid-beta protofibrils, toxic protein aggregates believed to play a key role in Alzheimer's disease progression. By targeting these aggregates, the therapy aims to: * Reduce amyloid buildup in the brain * Limit neuronal damage * Slow cognitive decline The therapy emerged from a long-standing research collaboration between Eisai Co., Ltd. and BioArctic AB. Global approvals and regulatory progress. Lecanemab has already received approval in more than 50 countries and regions, including: * United States * Japan * China * European Union * South Korea * Saudi Arabia Recent regulatory developments include: * U.S. FDA approval of subcutaneous maintenance dosing (August 2025) * Priority Review for a supplemental Biologics License Application, with a decision expected May 24, 2026 * Ongoing regulatory review of a subcutaneous formulation in multiple countries Ongoing clinical research. Several major clinical trials continue to investigate lecanemab's potential. One of the most notable is the AHEAD 3-45 trial, which focuses on individuals with preclinical Alzheimer's disease who have elevated amyloid levels but no cognitive symptoms. The trial is conducted through a public-private partnership involving: * Alzheimer's Clinical Trial Consortium * National Institute on Aging * Eisai Co., Ltd. * Biogen Inc. Another ongoing program is the Tau NexGen study, which investigates treatments for dominantly inherited Alzheimer's disease. Advancing Alzheimer's treatment strategies. The upcoming presentations at AD/PD 2026 reflect growing interest in real-world evidence, biomarker development, and long-term treatment outcomes for Alzheimer's disease therapies. As research continues, therapies like lecanemab may help refine early intervention strategies, potentially improving long-term outcomes for patients living with this progressive neurodegenerative condition. Optimize your trial insights with Clival Database. Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you. Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets. With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost. To add value, Clival further break down its analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible. Elevate your trial success rate with the cutting-edge insights from Clival database.

INACTIVE